Understanding BLENREP® (belantamab mafodotin-blmf)

This booklet discusses Blenrep® (belantamab mafodotin-blmf), an antibody-drug conjugate (ADC) that is a combination of a monoclonal antibody and a chemotherapy agent. Blenrep is the first and only medication in the ADC drug class that has been approved by the FDA to treat myeloma. Blenrep is unique because belantamab activates the immune system and attaches to the myeloma cell to deliver the toxic agent that kills the cancer.